SCM
TSHA icon

Sterling Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Sterling Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.31K Hold
1,411
– – ﹤0.01% 2618
2025
Q4 		$7.76K Buy
1,411
+896
+174% +$4.35K ﹤0.01% 2725
2025
Q3 		$1.68K Buy
515
+107
+26% +$303 ﹤0.01% 3008
2025
Q2 		$942 Buy
408
+243
+147% +$528 ﹤0.01% 3069
2025
Q1 		$229 Hold
165
– – ﹤0.01% 3069
2024
Q4 		$285 Hold
165
– – ﹤0.01% 3085
2024
Q3 		$332 Buy
+165
New +$362 ﹤0.01% 3009

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sterling Capital Management's TSHA Position: Q1 2026 in Review

Sterling Capital Management held its Taysha Gene Therapies (TSHA) position steady in Q1 2026 at 1,411 shares worth $6.31K. The position accounts for ﹤0.01% of the portfolio, ranked #2618.

Sterling Capital Management first reported a position in TSHA in Q3 2024 and has held it in 7 quarters since. The position peaked at $7.76K in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Sterling Capital Management held 1,411 shares of Taysha Gene Therapies worth $6.31K as of Q1 2026.
  • Sterling Capital Management left its Taysha Gene Therapies share count unchanged in Q1 2026.
  • Taysha Gene Therapies made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2618 holding.
  • Sterling Capital Management first reported a position in Taysha Gene Therapies in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's Taysha Gene Therapies position peaked at $7.76K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.